QuatRx's Ophena meets Phase III endpoints

QuatRx (Ann Arbor, Mich.) said top-line data showed that Ophena ospemifene met all co-primary endpoints in a Phase III trial to treat post-menopausal vaginal atrophy. Primary endpoints of the double-b...